Related references
Note: Only part of the references are listed.A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia A Retrospective Cohort Study
Marya D. Zilberberg et al.
CHEST (2019)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Takafumi Sato et al.
CLINICAL INFECTIOUS DISEASES (2019)
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Patrice Nordmann et al.
CLINICAL INFECTIOUS DISEASES (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
Michael R. Jacobs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
James A. Karlowsky et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Krystyna M. Kazmierczak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
Islam M. Ghazi et al.
PHARMACOLOGY (2018)
Stability of cefiderocol against clinically significant broad-spectrum oxacillinases
Laurent Poirel et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
Kenneth V I Rolston et al.
Open Forum Infectious Diseases (2018)
1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
Masakatsu Tsuji et al.
Open Forum Infectious Diseases (2018)
In Vitro Antibacterial Activity of S-649266 against Gram-negative Clinical Strains Collected in North America and Europe, 2015
Meredith Hackel et al.
Open Forum Infectious Diseases (2017)
Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
J. Dobias et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
Matthew E. Falagas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
Masakatsu Tsuji et al.
Open Forum Infectious Diseases (2017)
In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
Masakatsu Tsuji et al.
Open Forum Infectious Diseases (2017)
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
H. Wright et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Tsukasa Ito-Horiyama et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
Ya-Ting Chang et al.
FRONTIERS IN MICROBIOLOGY (2015)
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Joanna S. Brooke
CLINICAL MICROBIOLOGY REVIEWS (2012)
Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results
Raquel Girardello et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Stenotrophomonas maltophilia: an emerging opportunist human pathogen
W. John Looney et al.
LANCET INFECTIOUS DISEASES (2009)
Share Paper
